Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
Status:
Recruiting
Trial end date:
2022-08-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to figure out which commonly used antibiotic, cefoxitin or
piperacillin-tazobactam, is better at decreasing the rate of surgical site infections after
pancreatoduodenectomy.
Phase:
Phase 3
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Advocate Illinois Masonic Medical Center Albany Medical College Baptist Memorial Health Care Corporation Baylor Scott and White Health Brody School of Medicine at East Carolina University Emory University Fox Chase Cancer Center Gundersen Lutheran Medical Center Hackensack Meridian Health Hamilton Health Sciences Center Indiana University Intermountain Health Care, Inc. Jersey Shore Medical Center (Hackensack Meridian) Johns Hopkins University Massachusetts General Hospital Milton S. Hershey Medical Center Montefiore Medical Center/Albert Einstein College of Medicine Mount Sinai Hospital, New York North Shore University HealthSystem Northwestern University Providence Health & Services Rhode Island Hospital Stony Brook Medicine Sunnybrook Health Sciences Centre, Canada Temple University The Cleveland Clinic The Ohio State University Wexner Medical Center The Ottowa Hospital/University of Ottowa Thomas Jefferson University University of California, Davis University of Chicago University of Iowa University of Texas Southwestern Medical Center University of Utah University of Wisconsin, Madison Universtiy of Mississippi Medical Center Washington University School of Medicine
Treatments:
Cefotaxime Cefoxitin Penicillanic Acid Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam